Argilés, J. M., Busquets, S., Stemmler, B. & López-Soriano, F. J. Cancer cachexia: understanding the molecular basis. Nat. Rev. Cancer 14, 754–762 (2014).
Baracos, V. E. et al. Cancer-associated cachexia. Nat. Rev. Dis. Prim. 4, 17105 (2018).
Fearon, K. et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 12, 489–495 (2011).
Prado, C. M., Cushen, S. J., Orsso, C. E. & Ryan, A. M. Sarcopenia and cachexia in the era of obesity: clinical and nutritional impact. Proc. Nutr. Soc. 75, 188–198 (2016).
Martin, L. et al. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J. Clin. Oncol. 31, 1539–1547 (2013).
Argilés, J. M., López-Soriano, F. J., Stemmler, B. & Busquets, S. Cancer-associated cachexia – understanding the tumor macroenvironment and microenvironment to improve management. Nat. Rev. Clin. Oncol. 20, 250–264 (2023).
Bennani-Baiti, N. & Walsh, D. What is cancer anorexia-cachexia syndrome? A historical perspective. J. R. Coll. Physicians Edinb. 39, 257–262 (2009).
Schmidt, S. F., Rohm, M., Herzig, S. & Berriel Diaz, M. Cancer Cachexia: more than skeletal muscle wasting. Trends Cancer 4, 849–860 (2018).
Elinav, E. et al. Inflammation-induced cancer: crosstalk between tumors, immune cells and microorganisms. Nat. Rev. Cancer 13, 759–771 (2013).
Ganguly, K. & Kimmelman, A. C. Reprogramming of tissue metabolism during cancer metastasis. Trends Cancer 9, 461–471 (2023).
Fearon, K. C., Glass, D. J. & Guttridge, D. C. Cancer cachexia: mediators, signaling, and metabolic pathways. Cell Metab. 16, 153–166 (2012).
Strassmann, G., Fong, M., Kenney, J. S. & Jacob, C. O. Evidence for the involvement of interleukin 6 in experimental cancer cachexia. J. Clin. Investig. 89, 1681–1684 (1992).
Oliff, A. et al. Tumors secreting human TNF/cachectin induce cachexia in mice. Cell 50, 555–563 (1987).
de Visser, K. E. & Joyce, J. A. The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth. Cancer Cell 41, 374–403 (2023).
Mottini, C. et al. The cross-talk between the macro and micro-environment in precursor lesions of pancreatic cancer leads to new and promising circulating biomarkers. J. Exp. Clin. Cancer Res. 43, 198 (2024).
Evans, W. J. et al. Cachexia: a new definition. Clin. Nutr. 27, 793–799 (2008).
Arai, H. et al. Diagnosis and outcomes of cachexia in Asia: working Consensus Report from the Asian Working Group for Cachexia. J. Cachexia Sarcopenia Muscle 14, 1949–1958 (2023).
Xie, H. et al. AWGC2023 cachexia consensus as a valuable tool for predicting prognosis and burden in Chinese patients with cancer. J. Cachexia Sarcopenia Muscle 15, 2084–2093 (2024).
Zhang, F. M. et al. Characteristics and prognostic impact of cancer cachexia defined by the Asian Working Group for Cachexia consensus in patients with curable gastric cancer. Clin. Nutr. 43, 1524–1531 (2024).
Vigano, A., Del Fabbro, E., Bruera, E. & Borod, M. The cachexia clinic: from staging to managing nutritional and functional problems in advanced cancer patients. Crit. Rev. Oncog. 17, 293–303 (2012).
Douglas, E. & McMillan, D. C. Towards a simple objective framework for the investigation and treatment of cancer cachexia: the Glasgow Prognostic Score. Cancer Treat. Rev. 40, 685–691 (2014).
Silva, G. A. D., Wiegert, E. V. M., Calixto-Lima, L. & Oliveira, L. C. Clinical utility of the modified Glasgow Prognostic Score to classify cachexia in patients with advanced cancer in palliative care. Clin. Nutr. 39, 1587–1592 (2020).
Jin, Z. C. et al. Longitudinal body composition identifies hepatocellular carcinoma with cachexia following combined immunotherapy and target therapy (CHANCE2213). J. Cachexia Sarcopenia Muscle 15, 2705–2716 (2024).
Anker, M. S. et al. Orphan disease status of cancer cachexia in the USA and in the European Union: a systematic review. J. Cachexia Sarcopenia Muscle 10, 22–34 (2019).
Li, X. et al. Cancer cachexia statistics in China. Precision Nutrition. 1, https://doi.org/10.1097/PN1099.0000000000000008 (2022).
Latenstein, A. E. J. et al. Cachexia, dietetic consultation, and survival in patients with pancreatic and periampullary cancer: a multicenter cohort study. Cancer Med. 9, 9385–9395 (2020).
Takeda, T. et al. The impact of cachexia and sarcopenia in elderly pancreatic cancer patients receiving palliative chemotherapy. Int. J. Clin. Oncol. 26, 1293–1303 (2021).
Hou, Y. C. et al. The differential clinical impacts of cachexia and sarcopenia on the prognosis of advanced pancreatic cancer. Cancers. 14, 3137 (2022).
Furuse, J. et al. Effect of cancer cachexia on first-line chemotherapy in patients with advanced pancreatic cancer: a claims database study in Japan. Int. J. Clin. Oncol. 29, 456–463 (2024).
Shukuya, T. et al. Epidemiology, risk factors and impact of cachexia on patient outcome: results from the Japanese Lung Cancer Registry Study. J. Cachexia Sarcopenia Muscle 14, 1274–1285 (2023).
Roch, B. et al. Cachexia – sarcopenia as a determinant of disease control rate and survival in non-small lung cancer patients receiving immune-checkpoint inhibitors. Lung Cancer 143, 19–26 (2020).
Liu, C. A. et al. Nutrition impact symptoms: noteworthy prognostic indicators for lung cancer. Clin. Nutr. 42, 550–558 (2023).
Miura, K. et al. Impact of cachexia and first-line systemic therapy for previously untreated advanced non-small cell lung cancer: NEJ050A. J. Cachexia Sarcopenia Muscle 15, 2618–2628 (2024).
Zhang, J. et al. Cancer cachexia as a predictor of adverse outcomes in patients with non-small cell lung cancer: a meta-analysis. Clin. Nutr. 43, 1618–1625 (2024).
Kawachi, H. et al. Clinical impact of cancer cachexia on the outcome of patients with non-small cell lung cancer with PD-L1 tumor proportion scores of ≥50% receiving pembrolizumab monotherapy versus immune checkpoint inhibitor with chemotherapy. Oncoimmunology 14, 2442116 (2025).
White, R. et al. Determining the prevalence and severity of cancer cachexia in advanced non-small cell lung cancer and its relationship with chemotherapy outcomes. Support. Care Cancer 28, 4373–4380 (2020).
Li, H. et al. Effect of longitudinal changes of cachexia on the efficacy and toxicity of immune checkpoint inhibitors in esophageal squamous cell cancer (ESCC) patients. Nutrition 124, 112462 (2024).
Dijksterhuis, W. P. M. et al. Cachexia and dietetic interventions in patients with esophagogastric cancer: a multicenter cohort study. J. Natl Compr. Canc. Netw. 19, 144–152 (2021).
Brown, L. R. et al. Comparison between single- and multi-slice computed tomography body composition analysis in patients with oesophagogastric cancer. J. Cachexia Sarcopenia Muscle 16, e13673 (2025).
Brown, L. R. et al. The prognostic impact of pre-treatment cachexia in resectional surgery for oesophagogastric cancer: a meta-analysis and meta-regression. Br. J. Surg. 110, 1703–1711 (2023).
Olaechea, S. et al. Race, ethnicity, and socioeconomic factors as determinants of cachexia incidence and outcomes in a retrospective cohort of patients with gastrointestinal tract cancer. JCO Oncol. Pract. 19, 493–500 (2023).
Ruan, G. T. et al. Prognostic value of systemic inflammation and for patients with colorectal cancer cachexia. J. Cachexia Sarcopenia Muscle 14, 2813–2823 (2023).
Molfino, A. et al. Histomorphological and inflammatory changes of white adipose tissue in gastrointestinal cancer patients with and without cachexia. J. Cachexia Sarcopenia Muscle 13, 333–342 (2022).
Davis, E. W. et al. The association of body composition phenotypes before chemotherapy with epithelial ovarian cancer mortality. J. Natl. Cancer Inst. 116, 1513–1524 (2024).
Rich, N. E. et al. Cachexia is prevalent in patients with hepatocellular carcinoma and associated with worse prognosis. Clin. Gastroenterol. Hepatol. 20, e1157–e1169 (2022).
Kordes, M., Larsson, L., Engstrand, L. & Löhr, J. M. Pancreatic cancer cachexia: three dimensions of a complex syndrome. Br. J. Cancer 124, 1623–1636 (2021).
Agate, L. et al. Nutrition in advanced thyroid cancer patients. Nutrients. 14, 1298 (2022).
Mäkitie, A. A. et al. Managing cachexia in head and neck cancer: a systematic scoping review. Adv. Ther. 39, 1502–1523 (2022).
Zhu, R. et al. Updates on the pathogenesis of advanced lung cancer-induced cachexia. Thorac. Cancer 10, 8–16 (2019).
Demark-Wahnefried, W., Campbell, K. L. & Hayes, S. C. Weight management and its role in breast cancer rehabilitation. Cancer 118, 2277–2287 (2012).
Zhang, Q. et al. Association of systemic inflammation with survival in patients with cancer cachexia: results from a multicenter cohort study. J. Cachexia Sarcopenia Muscle 12, 1466–1476 (2021).
Mallard, J. et al. A single chemotherapy administration induces muscle atrophy, mitochondrial alterations and apoptosis in breast cancer patients. J. Cachexia Sarcopenia Muscle 15, 292–305 (2024).
Shibata, M. et al. A retrospective cohort study to investigate the incidence of cachexia during chemotherapy in patients with colorectal cancer. Adv. Ther. 37, 5010–5022 (2020).
Ben-Noun, L. L. The disease that caused weight loss in King David the Great. J. Gerontol. A Biol. Sci. Med. Sci. 59, 143–145 (2004).
Thibaut, M. M. et al. The microbiota-derived bile acid taurodeoxycholic acid improves hepatic cholesterol levels in mice with cancer cachexia. Gut Microbes 17, 2449586 (2025).
Petruzzelli, M. et al. A switch from white to brown fat increases energy expenditure in cancer-associated cachexia. Cell Metab. 20, 433–447 (2014).
Sah, R. P. et al. Phases of metabolic and soft tissue changes in months preceding a diagnosis of pancreatic Ductal Adenocarcinoma. Gastroenterology 156, 1742–1752 (2019).
Klatte, D. C. F. et al. Temporal trends in body composition and metabolic markers prior to diagnosis of pancreatic Ductal Adenocarcinoma. Clin. Gastroenterol. Hepatol. 22, 1830–1838.e1839 (2024).
Babic, A. et al. Adipose tissue and skeletal muscle wasting precede clinical diagnosis of pancreatic cancer. Nat. Commun. 14, 4317 (2023).
Garattini, S. et al. Anorexia and cancer in animals and man. Cancer Treat. Rev. 7, 115–139 (1980).
Qi, Y. et al. Agrp-negative arcuate NPY neurons drive feeding under positive energy balance via altering leptin responsiveness in POMC neurons. Cell Metab. 35, 979–995.e977 (2023).
Dallmann, R. et al. The orally active melanocortin-4 receptor antagonist BL-6020/979: a promising candidate for the treatment of cancer cachexia. J. Cachexia Sarcopenia Muscle 2, 163–174 (2011).
Zhu, X. et al. Melanocortin-4 receptor antagonist TCMCB07 ameliorates cancer- and chronic kidney disease-associated cachexia. J. Clin. Investig. 130, 4921–4934 (2020).
Sweeney, P., Gimenez, L. E., Hernandez, C. C. & Cone, R. D. Targeting the central melanocortin system for the treatment of metabolic disorders. Nat. Rev. Endocrinol. 19, 507–519 (2023).
Marks, D. L., Ling, N. & Cone, R. D. Role of the central melanocortin system in cachexia. Cancer Res. 61, 1432–1438 (2001).
Mosialou, I. et al. MC4R-dependent suppression of appetite by bone-derived lipocalin 2. Nature 543, 385–390 (2017).
Olson, B. et al. Lipocalin 2 mediates appetite suppression during pancreatic cancer cachexia. Nat. Commun. 12, 2057 (2021).
Steward, T. Endocrinology-informed neuroimaging in eating disorders: GLP1, orexins, and psilocybin. Trends Mol. Med. 30, 321–323 (2024).
Borner, T., Liberini, C. G., Lutz, T. A. & Riediger, T. Brainstem GLP-1 signaling contributes to cancer anorexia-cachexia syndrome in the rat. Neuropharmacology 131, 282–290 (2018).
Navarro, I. B. K., Schraner, M. & Riediger, T. Brainstem prolactin-releasing peptide contributes to cancer anorexia-cachexia syndrome in rats. Neuropharmacology 180, 108289 (2020).
Breit, S. N., Brown, D. A. & Tsai, V. W. The GDF15-GFRAL pathway in health and metabolic disease: friend or foe?. Annu. Rev. Physiol. 83, 127–151 (2021).
Braun, T. P. & Marks, D. L. Pathophysiology and treatment of inflammatory anorexia in chronic disease. J. Cachexia Sarcopenia Muscle 1, 135–145 (2010).
Burfeind, K. G. et al. TRIF is a key inflammatory mediator of acute sickness behavior and cancer cachexia. Brain. Behav. Immun. 73, 364–374 (2018).
Yeom, E. et al. Tumor-derived Dilp8/INSL3 induces cancer anorexia by regulating feeding neuropeptides via Lgr3/8 in the brain. Nat. Cell Biol. 23, 172–183 (2021).
Burfeind, K. G. et al. Circulating myeloid cells invade the central nervous system to mediate cachexia during pancreatic cancer. Elife 9, e54095 (2020).
Bindels, L. B. et al. Synbiotic approach restores intestinal homeostasis and prolongs survival in leukemic mice with cachexia. ISME J. 10, 1456–1470 (2016).
Chrysostomou, D., Roberts, L. A., Marchesi, J. R. & Kinross, J. M. Gut microbiota modulation of efficacy and toxicity of cancer chemotherapy and immunotherapy. Gastroenterology 164, 198–213 (2023).
Puppa, M. J. et al. Gut barrier dysfunction in the Apc(Min/+) mouse model of colon cancer cachexia. Biochim. Biophys. Acta 1812, 1601–1606 (2011).
Jia, H. et al. Eggshell membrane modulates gut microbiota to prevent murine pre-cachexia through suppression of T helper cell differentiation. J. Cachexia Sarcopenia Muscle 13, 2088–2101 (2022).
Ubachs, J. et al. Gut microbiota and short-chain fatty acid alterations in cachectic cancer patients. J. Cachexia Sarcopenia Muscle 12, 2007–2021 (2021).
Dumas, J. F. et al. Efficiency of oxidative phosphorylation in liver mitochondria is decreased in a rat model of peritoneal carcinosis. J. Hepatol. 54, 320–327 (2011).
Pötgens, S. A. et al. Multi-compartment metabolomics and metagenomics reveal major hepatic and intestinal disturbances in cancer cachectic mice. J. Cachexia Sarcopenia Muscle 12, 456–475 (2021).
Jones, A. et al. TSC22D4 is a molecular output of hepatic wasting metabolism. EMBO Mol. Med. 5, 294–308 (2013).
Kojima, Y. et al. Decreased liver B vitamin-related enzymes as a metabolic hallmark of cancer cachexia. Nat. Commun. 14, 6246 (2023).
Zechner, R. et al. FAT SIGNALS–lipases and lipolysis in lipid metabolism and signaling. Cell Metab. 15, 279–291 (2012).
Das, S. K. et al. Adipose triglyceride lipase contributes to cancer-associated cachexia. Science 333, 233–238 (2011).
Cannon, B. & Nedergaard, J. Brown adipose tissue: function and physiological significance. Physiol. Rev. 84, 277–359 (2004).
Tamucci, K. A., Namwanje, M., Fan, L. & Qiang, L. The dark side of browning. Protein Cell 9, 152–163 (2018).
Yin, X. et al. The evolving view of thermogenic fat and its implications in cancer and metabolic diseases. Signal Transduct. Target Ther. 7, 324 (2022).
Chen, X. et al. GRP75 triggers white adipose tissue browning to promote cancer-associated cachexia. Signal Transduct. Target Ther. 9, 253 (2024).
Rohm, M. et al. An AMP-activated protein kinase-stabilizing peptide ameliorates adipose tissue wasting in cancer cachexia in mice. Nat. Med. 22, 1120–1130 (2016).
Kir, S. et al. Tumor-derived PTH-related protein triggers adipose tissue browning and cancer cachexia. Nature 513, 100–104 (2014).
Kir, S. et al. PTH/PTHrP receptor mediates cachexia in models of kidney failure and cancer. Cell Metab. 23, 315–323 (2016).
Kahn, C. R., Wang, G. & Lee, K. Y. Altered adipose tissue and adipocyte function in the pathogenesis of metabolic syndrome. J. Clin. Investig. 129, 3990–4000 (2019).
Llovera, M. et al. Protein turnover in skeletal muscle of tumor-bearing transgenic mice overexpressing the soluble TNF receptor-1. Cancer Lett. 130, 19–27 (1998).
Martin, A., Gallot, Y. S. & Freyssenet, D. Molecular mechanisms of cancer cachexia-related loss of skeletal muscle mass: data analysis from preclinical and clinical studies. J. Cachexia Sarcopenia Muscle 14, 1150–1167 (2023).
Eldridge, A. G. & O’Brien, T. Therapeutic strategies within the ubiquitin proteasome system. Cell Death Differ. 17, 4–13 (2010).
Bodine, S. C. & Baehr, L. M. Skeletal muscle atrophy and the E3 ubiquitin ligases MuRF1 and MAFbx/atrogin-1. Am. J. Physiol. Endocrinol. Metab. 307, E469–E484 (2014).
de Castro, G. S. et al. Human cachexia induces changes in mitochondria, autophagy and apoptosis in the skeletal muscle. Cancers 11, 1264 (2019).
Zhang, R. et al. Corylifol A ameliorates muscle atrophy by inhibiting TAOK1/p38-MAPK/FoxO3 pathway in cancer cachexia. J. Cachexia Sarcopenia Muscle 14, 2098–2113 (2023).
Costelli, P., De Tullio, R., Baccino, F. M. & Melloni, E. Activation of Ca(2+)-dependent proteolysis in skeletal muscle and heart in cancer cachexia. Br. J. Cancer 84, 946–950 (2001).
Zhou, Z. et al. Acetyl-Coenzyme A Synthetase 2 Potentiates Macropinocytosis and muscle wasting through metabolic reprogramming in pancreatic cancer. Gastroenterology 163, 1281–1293.e1281 (2022).
Marino, S. et al. Paradoxical effects of JZL184, an inhibitor of monoacylglycerol lipase, on bone remodeling in healthy and cancer-bearing mice. EBioMedicine 44, 452–466 (2019).
Hain, B. A. et al. Zoledronic acid improves muscle function in healthy mice treated with chemotherapy. J. Bone Min. Res. 35, 368–381 (2020).
Essex, A. L. et al. Bisphosphonate treatment ameliorates chemotherapy-induced bone and muscle abnormalities in young mice. Front. Endocrinol.10, 809 (2019).
Bonetto, A. et al. Differential bone loss in mouse models of colon cancer cachexia. Front. Physiol. 7, 679 (2016).
Pin, F. et al. Non-bone metastatic cancers promote osteocyte-induced bone destruction. Cancer Lett. 520, 80–90 (2021).
Pin, F. et al. RANKL blockade reduces cachexia and bone loss induced by non-metastatic ovarian cancer in mice. J. Bone Min. Res. 37, 381–396 (2022).
Pittenger, M. F. et al. Multilineage potential of adult human mesenchymal stem cells. Science 284, 143–147 (1999).
Yu, J. et al. Bone marrow homeostasis is impaired via JAK/STAT and glucocorticoid signaling in cancer cachexia Model. Cancers 13, 1059 (2021).
Wang, B. et al. Inhibition of TGFβ improves hematopoietic stem cell niche and ameliorates cancer-related anemia. Stem Cell. Res. Ther. 12, 65 (2021).
Severinsen, M. C. K. & Pedersen, B. K. Muscle-organ crosstalk: the emerging roles of myokines. Endocr. Rev. 41, 594–609 (2020).
Morais, L. H., Schreiber, H. L. 4th & Mazmanian, S. K. The gut microbiota-brain axis in behavior and brain disorders. Nat. Rev. Microbiol. 19, 241–255 (2021).
Li, X. et al. Lipopolysaccharide-induced hypothalamic inflammation in cancer cachexia-anorexia is amplified by tumor-derived prostaglandin E2. J. Cachexia Sarcopenia Muscle 13, 3014–3027 (2022).
Suda, Y. et al. Peripheral-central network analysis of cancer cachexia status accompanied by the polarization of hypothalamic microglia with low expression of inhibitory immune checkpoint receptors. Mol. Brain. 17, 20 (2024).
Wen, J., Ding, Y., Wang, L. & Xiao, Y. Gut microbiome improves postoperative cognitive function by decreasing permeability of the blood-brain barrier in aged mice. Brain Res. Bull. 164, 249–256 (2020).
Khatib, M. N. et al. Ghrelin for the management of cachexia associated with cancer. Cochrane Database Syst. Rev. 2, Cd012229 (2018).
Wang, C. et al. The relationship of appetite-regulating hormones in the development of cardiac cachexia. Int. Heart J. 60, 384–391 (2019).
Choi, Y. K. et al. Effect of Sipjeondaebo-tang on cancer-induced anorexia and cachexia in CT-26 tumor-bearing mice. Mediators Inflamm. 2014, 736563 (2014).
Li, Y. et al. Systematic characterization of the disruption of intestine during liver tumor progression in the xmrk oncogene transgenic zebrafish model. Cells 11, 1810 (2022).
das Neves, R. X. et al. Cachexia causes time-dependent activation of the inflammasome in the liver. J. Cachexia Sarcopenia Muscle 14, 1621–1630 (2023).
Modica, S. et al. Selective activation of nuclear bile acid receptor FXR in the intestine protects mice against cholestasis. Gastroenterology 142, 355–365 (2012). e351-354.
Feng, L. et al. Bile acid metabolism dysregulation associates with cancer cachexia: roles of liver and gut microbiome. J. Cachexia Sarcopenia Muscle 12, 1553–1569 (2021).
Thibaut, M. M. et al. Bile acid dysregulation is intrinsically related to cachexia in tumor-bearing mice. Cancers 13, 6389 (2021).
Dong, F. et al. Intestinal microbiota-derived tryptophan metabolites are predictive of Ah receptor activity. Gut Microbes 12, 1–24 (2020).
Dolly, A. et al. Impairment of aryl hydrocarbon receptor signaling promotes hepatic disorders in cancer cachexia. J. Cachexia Sarcopenia Muscle 14, 1569–1582 (2023).
Wu, S. Y. et al. Polysaccharide of ganoderma lucidum ameliorates cachectic myopathy induced by the combination cisplatin plus docetaxel in mice. Microbiol Spectr. 11, e0313022 (2023).
Jumpertz, R. et al. Energy-balance studies reveal associations between gut microbes, caloric load, and nutrient absorption in humans. Am. J. Clin. Nutr. 94, 58–65 (2011).
Sakakida, T. et al. Water-soluble dietary fiber alleviates cancer-induced muscle wasting through changes in gut microenvironment in mice. Cancer Sci. 113, 1789–1800 (2022).
Qiu, Y. et al. Depletion of gut microbiota induces skeletal muscle atrophy by FXR-FGF15/19 signaling. Ann. Med. 53, 508–522 (2021).
Zhong, W. et al. Gut dysbiosis promotes prostate cancer progression and docetaxel resistance via activating NF-κB-IL6-STAT3 axis. Microbiome 10, 94 (2022).
Pekkala, S. et al. Blocking activin receptor ligands is not sufficient to rescue cancer-associated gut Microbiota-A role for gut microbial flagellin in colorectal cancer and cachexia?. Cancers 11, 1799 (2019).
Costa, R. G. F. et al. Cancer cachexia induces morphological and inflammatory changes in the intestinal mucosa. J. Cachexia Sarcopenia Muscle 10, 1116–1127 (2019).
Quinn, L. S. et al. Oversecretion of interleukin-15 from skeletal muscle reduces adiposity. Am. J. Physiol. Endocrinol. Metab. 296, E191–E202 (2009).
Molanouri Shamsi, M. et al. Combined effect of aerobic interval training and selenium nanoparticles on expression of IL-15 and IL-10/TNF-α ratio in skeletal muscle of 4T1 breast cancer mice with cachexia. Cytokine 90, 100–108 (2017).
Loumaye, A. et al. Role of Activin A and myostatin in human cancer cachexia. J. Clin. Endocrinol. Metab. 100, 2030–2038 (2015).
Franz, K. et al. Higher serum levels of fibroblast growth factor 21 in old patients with cachexia. Nutrition 63-64, 81–86 (2019).
Fu, T. et al. Mitophagy directs muscle-adipose crosstalk to alleviate dietary obesity. Cell Rep. 23, 1357–1372 (2018).
Lemecha, M. et al. Lcn2 mediates adipocyte-muscle-tumor communication and hypothermia in pancreatic cancer cachexia. Mol. Metab. 66, 101612 (2022).
Campderrós, L. et al. Brown adipocytes secrete GDF15 in response to thermogenic activation. Obesity 27, 1606–1616 (2019).
Suzuki, H. et al. Clinical and tumor characteristics of patients with high serum levels of growth differentiation factor 15 in advanced pancreatic cancer. Cancers. 13, 4842 (2021).
Rupert, J. E. et al. Tumor-derived IL-6 and trans-signaling among tumor, fat, and muscle mediate pancreatic cancer cachexia. J. Exp. Med. 218, e20190450 (2021).
Han, M. S. et al. Regulation of adipose tissue inflammation by interleukin 6. Proc. Natl. Acad. Sci. USA 117, 2751–2760 (2020).
Waning, D. L. et al. Excess TGF-β mediates muscle weakness associated with bone metastases in mice. Nat. Med. 21, 1262–1271 (2015).
Shen, H., Grimston, S., Civitelli, R. & Thomopoulos, S. Deletion of connexin43 in osteoblasts/osteocytes leads to impaired muscle formation in mice. J. Bone Min. Res. 30, 596–605 (2015).
Bonnet, N. et al. RANKL inhibition improves muscle strength and insulin sensitivity and restores bone mass. J. Clin. Investig. 129, 3214–3223 (2019).
Dankbar, B. et al. Myostatin is a direct regulator of osteoclast differentiation and its inhibition reduces inflammatory joint destruction in mice. Nat. Med. 21, 1085–1090 (2015).
Kitase, Y. et al. β-aminoisobutyric Acid, l-BAIBA, is a muscle-derived osteocyte survival factor. Cell Rep. 22, 1531–1544 (2018).
Engeli, S. Central and peripheral cannabinoid receptors as therapeutic targets in the control of food intake and body weight. Handb. Exp. Pharmacol. 209, 357–381 (2012).
Molfino, A., Gioia, G., Rossi Fanelli, F. & Laviano, A. Contribution of neuroinflammation to the pathogenesis of cancer cachexia. Mediators Inflamm. 2015, 801685 (2015).
Bernstein, I. L. Neutral mediation of food aversions and anorexia induced by tumor necrosis factor and tumors. Neurosci. Biobehav. Rev. 20, 177–181 (1996).
Borner, T. et al. Anorexia-cachexia syndrome in hepatoma tumor-bearing rats requires the area postrema but not vagal afferents and is paralleled by increased MIC-1/GDF15. J. Cachexia Sarcopenia Muscle 8, 417–427 (2017).
Piffar, P. M. et al. Naproxen, clenbuterol and insulin administration ameliorates cancer cachexia and reduce tumor growth in Walker 256 tumor-bearing rats. Cancer Lett. 201, 139–148 (2003).
Busquets, S. et al. Anticachectic effects of formoterol: a drug for potential treatment of muscle wasting. Cancer Res. 64, 6725–6731 (2004).
Suriben, R. et al. Antibody-mediated inhibition of GDF15-GFRAL activity reverses cancer cachexia in mice. Nat. Med. 26, 1264–1270 (2020).
Xie, H. et al. An immune-sympathetic neuron communication axis guides adipose tissue browning in cancer-associated cachexia. Proc. Natl. Acad. Sci. USA 119, e2112840119 (2022).
Nukaga, S. et al. Combined administration of lauric acid and glucose improved cancer-derived cardiac atrophy in a mouse cachexia model. Cancer Sci. 111, 4605–4615 (2020).
Wei, L. et al. 2-Deoxy-D-glucose alleviates cancer cachexia-induced muscle wasting by enhancing ketone metabolism and inhibiting the cori cycle. Cells 11, 2987 (2022).
DeWys, W. D. Pathophysiology of cancer cachexia: current understanding and areas for future research. Cancer Res. 42, 721s–726s (1982).
Baker, S. A. & Rutter, J. Metabolites as signaling molecules. Nat. Rev. Mol. Cell Biol. 24, 355–374 (2023).
Lin, J. G. et al. Metabolic modulation of transcription: the role of one-carbon metabolism. Cell Chem. Biol. 29, (2022).
Nalbantoglu, S. & Karadag, A. Metabolomics bridging proteomics along metabolites/oncometabolites and protein modifications: Paving the way toward integrative multiomics. J. Pharm. Biomed. Anal. 199, 114031 (2021).
Rabinowitz, J. D. & Enerbäck, S. Lactate: the ugly duckling of energy metabolism. Nat. Metab. 2, 566–571 (2020).
Warburg, O. On the origin of cancer cells. Science 123, 309–314 (1956).
McGovern, J. et al. Lactate dehydrogenase: relationship with the diagnostic GLIM criterion for cachexia in patients with advanced cancer. Br. J. Cancer 128, 760–765 (2023).
Pin, F. et al. Cachexia induced by cancer and chemotherapy yield distinct perturbations to energy metabolism. J. Cachexia Sarcopenia Muscle 10, 140–154 (2019).
Pin, F. et al. PDK4 drives metabolic alterations and muscle atrophy in cancer cachexia. FASEB J. 33, 7778–7790 (2019).
Mannelli, M. et al. STAT3 signaling drives LDH Up-regulation and adiponectin down-regulation in cachectic adipocytes. Int. J. Mol. Sci. 24, 16343 (2023).
Felmlee, M. A. et al. Monocarboxylate Transporters (SLC16): function, regulation, and role in health and disease. Pharmacol. Rev. 72, 466–485 (2020).
Magistretti, P. J. & Allaman, I. Lactate in the brain: from metabolic end-product to signaling molecule. Nat. Rev. Neurosci. 19, 235–249 (2018).
Silberbauer, C. J., Surina-Baumgartner, D. M., Arnold, M. & Langhans, W. Prandial lactate infusion inhibits spontaneous feeding in rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 278, R646–R653 (2000).
Liu, X. et al. Activation of GPR81 by lactate drives tumor-induced cachexia. Nat. Metab. 6, 708–723 (2024).
Nikooie, R., Moflehi, D. & Zand, S. Lactate regulates autophagy through ROS-mediated activation of ERK1/2/m-TOR/p-70S6K pathway in skeletal muscle. J. Cell Commun. Signal 15, 107–123 (2021).
Feng, Q. et al. Lactate increases stemness of CD8 + T cells to augment anti-tumor immunity. Nat. Commun. 13, 4981 (2022).
Noe, J. T. et al. Lactate supports a metabolic-epigenetic link in macrophage polarization. Sci. Adv. 7, eabi8602 (2021).
Zhang, D. et al. Metabolic regulation of gene expression by histone lactylation. Nature 574, 575–580 (2019).
Brand, A. et al. LDHA-associated lactic acid production blunts tumor immunosurveillance by T and NK Cells. Cell Metab. 24, 657–671 (2016).
Linares, J. F. et al. The lactate-NAD(+) axis activates cancer-associated fibroblasts by downregulating p62. Cell Rep. 39, 110792 (2022).
Rastogi, S. et al. Lactate acidosis and simultaneous recruitment of TGF-β leads to alter plasticity of hypoxic cancer cells in tumor microenvironment. Pharm. Ther. 250, 108519 (2023).
Mannelli, M. et al. Pyruvate prevents the onset of the cachectic features and metabolic alterations in myotubes downregulating STAT3 signaling. FASEB J. 36, e22598 (2022).
Jiang, X. et al. Pyruvate dehydrogenase B regulates myogenic differentiation via the FoxP1-Arih2 axis. J. Cachexia Sarcopenia Muscle 14, 606–621 (2023).
Kim, M. J. et al. The role of pyruvate metabolism in mitochondrial quality control and inflammation. Mol. Cells 46, 259–267 (2023).
Elia, I. et al. Tumor cells dictate anti-tumor immune responses by altering pyruvate utilization and succinate signaling in CD8(+) T cells. Cell Metab. 34, 1137–1150.e1136 (2022).
Shu, Y. et al. Intervening pyruvate carboxylase stunts tumor growth by strengthening anti-tumor actions of tumor-associated macrophages. Signal Transduct. Target Ther. 7, 34 (2022).
Wenes, M. et al. The mitochondrial pyruvate carrier regulates memory T cell differentiation and antitumor function. Cell Metab. 34, 731–746.e739 (2022).
Cui, P. et al. Metabolic profiling of tumors, sera, and skeletal muscles from an orthotopic murine model of gastric cancer associated-cachexia. J. Proteome Res. 18, 1880–1892 (2019).
Ruiz, B. I. et al. Alpha-Ketoglutarate regulates Tnfrsf12a/Fn14 expression via histone modification and prevents cancer-induced cachexia. Genes. 14, 1818 (2023).
Tan, H. et al. Ketoglutaric acid can reprogram the immunophenotype of triple-negative breast cancer after radiotherapy and improve the therapeutic effect of anti-PD-L1. J. Transl. Med. 21, 462 (2023).
Cai, Z. et al. Targeting PHGDH reverses the immunosuppressive phenotype of tumor-associated macrophages through α-ketoglutarate and mTORC1 signaling. Cell. Mol. Immunol. 21, 448–465 (2024).
Matias, M. I. et al. Regulatory T cell differentiation is controlled by αKG-induced alterations in mitochondrial metabolism and lipid homeostasis. Cell Rep. 37, 109911 (2021).
Flint, T. R. et al. Tumor-Induced IL-6 reprograms host metabolism to suppress anti-tumor immunity. Cell Metab. 24, 672–684 (2016).
Goncalves, M. D. et al. Fenofibrate prevents skeletal muscle loss in mice with lung cancer. Proc. Natl. Acad. Sci. USA 115, E743–e752 (2018).
von Renesse, J. et al. Tumor catabolism independent of malnutrition and inflammation in upper GI cancer patients revealed by longitudinal metabolomics. J. Cachexia Sarcopenia Muscle 14, 298–309 (2023).
Mulligan, H. D. & Tisdale, M. J. Metabolic substrate utilization by tumor and host tissues in cancer cachexia. Biochem. J. 277, 321–326 (1991).
Zhou, Y. et al. Exploring the therapeutic potential of Ethyl 3-hydroxybutyrate in alleviating skeletal muscle wasting in cancer cachexia. Biomolecules. 13, 1330 (2023).
Arneson-Wissink, P. C. et al. Hepatic signal transducer and activator of transcription-3 signaling drives early-stage pancreatic cancer cachexia via suppressed ketogenesis. J. Cachexia Sarcopenia Muscle 15, 975–988 (2024).
Ferrer, M. et al. Ketogenic diet promotes tumor ferroptosis but induces relative corticosterone deficiency that accelerates cachexia. Cell Metab. 35, 1147–1162.e1147 (2023).
Wei, R. et al. Ketogenesis attenuates KLF5-dependent production of CXCL12 to overcome the immunosuppressive tumor microenvironment in colorectal cancer. Cancer Res. 82, 1575–1588 (2022).
Luda, K. M. et al. Ketolysis drives CD8(+) T cell effector function through effects on histone acetylation. Immunity 56, 2021–2035.e2028 (2023).
Hosios, A. M. et al. Amino acids rather than glucose account for the majority of cell mass in proliferating mammalian cells. Dev. Cell 36, 540–549 (2016).
Tabe, Y., Lorenzi, P. L. & Konopleva, M. Amino acid metabolism in hematologic malignancies and the era of targeted therapy. Blood 134, 1014–1023 (2019).
Yang, L. et al. Amino acid metabolism in immune cells: essential regulators of the effector functions, and promising opportunities to enhance cancer immunotherapy. J. Hematol. Oncol. 16, 59 (2023).
Cala, M. P. et al. Multiplatform plasma fingerprinting in cancer cachexia: a pilot observational and translational study. J. Cachexia Sarcopenia Muscle 9, 348–357 (2018).
Bozzetti, F. & Bozzetti, V. Is the intravenous supplementation of amino acid to cancer patients adequate? A critical appraisal of literature. Clin. Nutr. 32, 142–146 (2013).
Zea, A. H. et al. L-Arginine modulates CD3zeta expression and T-cell function in activated human T lymphocytes. Cell. Immunol. 232, 21–31 (2004).
Lian, G. et al. Glutathione de novo synthesis but not recycling process coordinates with glutamine catabolism to control redox homeostasis and directs murine T-cell differentiation. Elife. 7, e36158 (2018).
Jha, A. K. et al. Network integration of parallel metabolic and transcriptional data reveals metabolic modules that regulate macrophage polarization. Immunity 42, 419–430 (2015).
Oh, M. H. et al. Targeting glutamine metabolism enhances tumor-specific immunity by modulating suppressive myeloid cells. J. Clin. Investig. 130, 3865–3884 (2020).
Sinclair, L. V. et al. Antigen receptor control of methionine metabolism in T cells. Elife 8, e44210 (2019).
Jiménez-Alonso, J. J. & López-Lázaro, M. Dietary manipulation of amino acids for cancer therapy. Nutrients 15, 2879 (2023).
Engelen, M. et al. High anabolic potential of essential amino acid mixtures in advanced non-small cell lung cancer. Ann. Oncol. 26, 1960–1966 (2015).
Aliwa, B. et al. Altered gut microbiome, bile acid composition and metabolome in sarcopenia in liver cirrhosis. J. Cachexia Sarcopenia Muscle 14, 2676–2691 (2023).
Chen, L. et al. Bckdk-mediated branch chain amino acid metabolism reprogramming contributes to muscle atrophy during cancer cachexia. Mol. Nutr. Food Res. 68, e2300577 (2024).
Mora, S. & Adegoke, O. A. J. Maintenance of the branched-chain amino acid transporter LAT1 counteracts myotube atrophy following chemotherapy. Am. J. Physiol. Cell Physiol. 326, C866–c879 (2024).
Baek, M. O. et al. Self-transducible LRS-UNE-L peptide enhances muscle regeneration. J. Cachexia Sarcopenia Muscle 13, 1277–1288 (2022).
Viana, L. R. et al. Leucine-rich diet improved muscle function in cachectic walker 256 tumor-bearing wistar rats. Cells. 10, 3272 (2021).
Toneto, A. T. et al. Nutritional leucine supplementation attenuates cardiac failure in tumor-bearing cachectic animals. J. Cachexia Sarcopenia Muscle 7, 577–586 (2016).
Miyaguti, N., Oliveira, S. C. P. & Gomes-Marcondes, M. C. C. Maternal leucine-rich diet minimizes muscle mass loss in tumor-bearing adult rat offspring by improving the balance of muscle protein synthesis and degradation. Biomolecules. 9, 229 (2019).
Salomão, E. M. & Gomes-Marcondes, M. C. Light aerobic physical exercise in combination with leucine and/or glutamine-rich diet can improve the body composition and muscle protein metabolism in young tumor-bearing rats. J. Physiol. Biochem. 68, 493–501 (2012).
Caperuto, E. C. et al. Beta-hydoxy-beta-methylbutyrate supplementation affects Walker 256 tumor-bearing rats in a time-dependent manner. Clin. Nutr. 26, 117–122 (2007).
Liu, K. A., Lashinger, L. M., Rasmussen, A. J. & Hursting, S. D. Leucine supplementation differentially enhances pancreatic cancer growth in lean and overweight mice. Cancer Metab. 2, 6 (2014).
Schrems, E. R. et al. Leucine supplementation exacerbates morbidity in male but not female mice with colorectal cancer-induced cachexia. Nutrients 15, 4570 (2023).
Lautaoja, J. H. et al. Muscle and serum metabolomes are dysregulated in colon-26 tumor-bearing mice despite amelioration of cachexia with activin receptor type 2B ligand blockade. Am. J. Physiol. Endocrinol. Metab. 316, E852–e865 (2019).
Ninomiya, S. et al. Low levels of serum tryptophan underlie skeletal muscle atrophy. Nutrients. 12, 978 (2020).
Qiu, X. et al. Metabolic signatures and potential biomarkers for the diagnosis and treatment of colon cancer cachexia. Acta Biochim. Biophys. Sin. 55, 1913–1924 (2023).
Kunz, H. E. et al. Methylarginine metabolites are associated with attenuated muscle protein synthesis in cancer-associated muscle wasting. J. Biol. Chem. 295, 17441–17459 (2020).
Kunzke, T. et al. Derangements of amino acids in cachectic skeletal muscle are caused by mitochondrial dysfunction. J. Cachexia Sarcopenia Muscle 11, 226–240 (2020).
Wu, J. et al. Cyst(e)ine in nutrition formulation promotes colon cancer growth and chemoresistance by activating mTORC1 and scavenging ROS. Signal Transduct. Target Ther. 6, 188 (2021).
Kudamatsu, H. et al. Ameliorating effects of cystine and theanine in a cancer cachexia mouse model. J. Pharmacol. Sci. 152, 163–166 (2023).
Baumert, P. et al. Skeletal muscle hypertrophy rewires glucose metabolism: An experimental investigation and systematic review. J. Cachexia Sarcopenia Muscle 15, 989–1002 (2024).
Sirniö, P. et al. Alterations in serum amino-acid profile in the progression of colorectal cancer: associations with systemic inflammation, tumor stage and patient survival. Br. J. Cancer 120, 238–246 (2019).
Ham, D. J. et al. Glycine administration attenuates skeletal muscle wasting in a mouse model of cancer cachexia. Clin. Nutr. 33, 448–458 (2014).
Posa, D. K. et al. Skeletal muscle analysis of cancer patients reveals a potential role for carnosine in muscle wasting. J. Cachexia Sarcopenia Muscle 14, 1802–1814 (2023).
Tůma, P., Hložek, T., Kamišová, J. & Gojda, J. Monitoring of circulating amino acids in patients with pancreatic cancer and cancer cachexia using capillary electrophoresis and contactless conductivity detection. Electrophoresis 42, 1885–1891 (2021).
Fracaro, L. et al. Walker 256 tumor-bearing rats demonstrate altered interstitial cells of Cajal. Effects on ICC in the Walker 256 tumor model. Neurogastroenterol. Motil. 28, 101–115 (2016).
Vicentini, G. E. et al. Does l-glutamine-supplemented diet extenuate NO-mediated damage on myenteric plexus of Walker 256 tumor-bearing rats?. Food Res. Int. 101, 24–34 (2017).
Zhou, L., Lu, R., Huang, C. & Lin, D. Taurine protects C2C12 myoblasts from impaired cell proliferation and myotube differentiation under cisplatin-induced ROS Exposure. Front. Mol. Biosci. 8, 685362 (2021).
Deminice, R. et al. Creatine supplementation prevents hyperhomocysteinemia, oxidative stress and cancer-induced cachexia progression in Walker-256 tumor-bearing rats. Amino Acids 48, 2015–2024 (2016).
Cella, P. S. et al. Creatine supplementation in Walker-256 tumor-bearing rats prevents skeletal muscle atrophy by attenuating systemic inflammation and protein degradation signaling. Eur. J. Nutr. 59, 661–669 (2020).
Gramignano, G. et al. Efficacy of l-carnitine administration on fatigue, nutritional status, oxidative stress, and related quality of life in 12 advanced cancer patients undergoing anticancer therapy. Nutrition 22, 136–145 (2006).
Liu, S. et al. L-carnitine ameliorates cancer cachexia in mice by regulating the expression and activity of carnitine palmityl transferase. Cancer Biol. Ther. 12, 125–130 (2011).
Silvério, R., Laviano, A., Rossi Fanelli, F. & Seelaender, M. L-Carnitine induces recovery of liver lipid metabolism in cancer cachexia. Amino Acids 42, 1783–1792 (2012).
de Carvalho, C. & Caramujo, M. J. The various roles of fatty acids. Molecules. 23, 2583 (2018).
Jin, C. et al. Low expression of ELOVL6 may be involved in fat loss in white adipose tissue of cancer-associated cachexia. Lipids Health Dis. 23, 144 (2024).
Gumpper-Fedus, K. et al. Altered plasma fatty acid abundance is associated with cachexia in treatment-naïve pancreatic cancer. Cells 11, 910 (2022).
Wang, Y. P. et al. The involvement and possible targeting of cardiolipins degradation and disturbed linoleic acid metabolism in cardiac atrophy under cancer cachexia. Eur. J. Pharmacol. 985, 177108 (2024).
Calder, P. C. Omega-3 fatty acids and inflammatory processes: from molecules to man. Biochem. Soc. Trans. 45, 1105–1115 (2017).
Murphy, R. A. et al. Skeletal muscle depletion is associated with reduced plasma (n-3) fatty acids in non-small cell lung cancer patients. J. Nutr. 140, 1602–1606 (2010).
Colomer, R. et al. N-3 fatty acids, cancer and cachexia: a systematic review of the literature. Br. J. Nutr. 97, 823–831 (2007).
Burns, C. P. et al. Phase II study of high-dose fish oil capsules for patients with cancer-related cachexia. Cancer 101, 370–378 (2004).
Werner, K. et al. Dietary supplementation with n-3-fatty acids in patients with pancreatic cancer and cachexia: marine phospholipids versus fish oil – a randomized controlled double-blind trial. Lipids Health Dis. 16, 104 (2017).
Whitehouse, A. S., Smith, H. J., Drake, J. L. & Tisdale, M. J. Mechanism of attenuation of skeletal muscle protein catabolism in cancer cachexia by eicosapentaenoic acid. Cancer Res. 61, 3604–3609 (2001).
Whitehouse, A. S. & Tisdale, M. J. Increased expression of the ubiquitin-proteasome pathway in murine myotubes by proteolysis-inducing factor (PIF) is associated with activation of the transcription factor NF-kappaB. Br. J. Cancer 89, 1116–1122 (2003).
Yang, Y. H. et al. Docosahexaenoic acid-enriched phospholipids and eicosapentaenoic acid-enriched phospholipids inhibit tumor necrosis factor-alpha-induced lipolysis in 3T3-L1 adipocytes by activating sirtuin 1 pathways. Food Funct. 12, 4783–4796 (2021).
Freitas, R. D. S. et al. Targeting FFA1 and FFA4 receptors in cancer-induced cachexia. Am. J. Physiol. Endocrinol. Metab. 319, E877–e892 (2020).
Fu, Y. et al. Associations among dietary omega-3 polyunsaturated fatty acids, the gut microbiota, and intestinal immunity. Mediators Inflamm. 2021, 8879227 (2021).
Im, D. S. Functions of omega-3 fatty acids and FFA4 (GPR120) in macrophages. Eur. J. Pharmacol. 785, 36–43 (2016).
Wu, S. et al. The ω-3 polyunsaturated fatty acid docosahexaenoic acid enhances NK-Cell antitumor effector functions. Cancer Immunol. Res. 12, 744–758 (2024).
Munson, P. V. et al. Polyunsaturated fatty acid-bound α-Fetoprotein promotes immune suppression by altering human dendritic cell metabolism. Cancer Res. 83, 1543–1557 (2023).
Kornfeld, S. et al. Reducing endothelial NOS activation and interstitial fluid pressure with n-3 PUFA offset tumor chemoresistance. Carcinogenesis 33, 260–267 (2012).
Mori, T. et al. Giving combined medium-chain fatty acids and glucose protects against cancer-associated skeletal muscle atrophy. Cancer Sci. 110, 3391–3399 (2019).
Nishida, R. et al. Differential effects of three medium-chain fatty acids on mitochondrial quality control and skeletal muscle maturation. Antioxidants. 13, 821 (2024).
Tisdale, M. J. & Brennan, R. A. A comparison of long-chain triglycerides and medium-chain triglycerides on weight loss and tumor size in a cachexia model. Br. J. Cancer 58, 580–583 (1988).
Zhang, X. et al. Pro-phagocytic function and structural basis of GPR84 signaling. Nat. Commun. 14, 5706 (2023).
Liu, H. et al. The metabolite butyrate produced by gut microbiota inhibits cachexia-associated skeletal muscle atrophy by regulating intestinal barrier function and macrophage polarization. Int. Immunopharmacol. 124, 111001 (2023).
Yang, W. et al. Intestinal microbiota-derived short-chain fatty acids regulation of immune cell IL-22 production and gut immunity. Nat. Commun. 11, 4457 (2020).
Cheung, W. W. et al. Vitamin D repletion ameliorates adipose tissue browning and muscle wasting in infantile nephropathic cystinosis-associated cachexia. J. Cachexia Sarcopenia Muscle 11, 120–134 (2020).
Zhou, P. et al. Metabolic advantage of 25(OH)D(3) versus 1,25(OH)(2)D(3) supplementation in infantile nephropathic cystinosis-associated adipose tissue browning and muscle wasting. Cells. 11, 3264 (2022).
Hochwald, S. N. et al. Depletion of high energy phosphate compouds in the tumor-bearing state and reversal after tumor resection. Surgery 120, 534–541 (1996).
Konishi, M. et al. Febuxostat improves outcome in a rat model of cancer cachexia. J. Cachexia Sarcopenia Muscle 6, 174–180 (2015).
Raun, S. H. et al. Adenosine monophosphate-activated protein kinase is elevated in human cachectic muscle and prevents cancer-induced metabolic dysfunction in mice. J. Cachexia Sarcopenia Muscle 14, 1631–1647 (2023).
Beltrà, M. et al. NAD(+) repletion with niacin counteracts cancer cachexia. Nat. Commun. 14, 1849 (2023).
Park, J. M. et al. Nicotinamide riboside vitamin B3 mitigated C26 adenocarcinoma-induced cancer cachexia. Front. Pharmacol. 12, 665493 (2021).
Le Moal, E. et al. Redox control of skeletal muscle regeneration. Antioxid. Redox Signal. 27, 276–310 (2017).
Puig-Vilanova, E. et al. Oxidative stress, redox signaling pathways, and autophagy in cachectic muscles of male patients with advanced COPD and lung cancer. Free Radic. Biol. Med. 79, 91–108 (2015).
Gomes-Marcondes, M. C. & Tisdale, M. J. Induction of protein catabolism and the ubiquitin‒proteasome pathway by mild oxidative stress. Cancer Lett. 180, 69–74 (2002).
Min, K. et al. Increased mitochondrial emission of reactive oxygen species and calpain activation are required for doxorubicin-induced cardiac and skeletal muscle myopathy. J. Physiol. 593, 2017–2036 (2015).
Tan, P. L., Shavlakadze, T., Grounds, M. D. & Arthur, P. G. Differential thiol oxidation of the signaling proteins Akt, PTEN or PP2A determines whether Akt phosphorylation is enhanced or inhibited by oxidative stress in C2C12 myotubes derived from skeletal muscle. Int. J. Biochem. Cell Biol. 62, 72–79 (2015).
Kim, J. & Bae, J. S. Tumor-associated macrophages and neutrophils in tumor microenvironment. Mediators Inflamm. 2016, 6058147 (2016).
Markov, S. D., Gonzalez, D. & Mehla, K. Preclinical models for studying the impact of macrophages on cancer cachexia. Curr. Protoc. Pharmacol. 91, e80 (2020).
Odegaard, J. I. & Chawla, A. Type 2 responses at the interface between immunity and fat metabolism. Curr. Opin. Immunol. 36, 67–72 (2015).
Nguyen, K. D. et al. Alternatively activated macrophages produce catecholamines to sustain adaptive thermogenesis. Nature 480, 104–108 (2011).
Qiu, Y. et al. Eosinophils and type 2 cytokine signaling in macrophages orchestrate development of functional beige fat. Cell 157, 1292–1308 (2014).
Wu, S. et al. M2 macrophages independently promote beige adipogenesis via blocking adipocyte Ets1. Nat. Commun. 15, 1646 (2024).
Zeng, X. et al. M2 macrophage-derived TGF-β induces age-associated loss of adipogenesis through progenitor cell senescence. Mol. Metab. 84, 101943 (2024).
Batista, M. L. Jr. et al. Cachexia-associated adipose tissue morphological rearrangement in gastrointestinal cancer patients. J. Cachexia Sarcopenia Muscle 7, 37–47 (2016).
Erdem, M. et al. Macrophages protect against loss of adipose tissue during cancer cachexia. J. Cachexia Sarcopenia Muscle 10, 1128–1142 (2019).
Shukla, S. K. et al. Macrophages potentiate STAT3 signaling in skeletal muscles and regulate pancreatic cancer cachexia. Cancer Lett. 484, 29–39 (2020).
Liu, M. et al. The crosstalk between macrophages and cancer cells potentiates pancreatic cancer cachexia. Cancer Cell 42, 885–903.e884 (2024).
Johnston, A. J. et al. Targeting of Fn14 prevents cancer-induced cachexia and prolongs survival. Cell 162, 1365–1378 (2015).
Tonkin, J. et al. Monocyte/Macrophage-derived IGF-1 orchestrates murine skeletal muscle regeneration and modulates autocrine polarization. Mol. Ther. 23, 1189–1200 (2015).
Pryce, B. R. et al. Muscle inflammation is regulated by NF-κB from multiple cells to control distinct states of wasting in cancer cachexia. Cell Rep. 43, 114925 (2024).
Penafuerte, C. A. et al. Identification of neutrophil-derived proteases and angiotensin II as biomarkers of cancer cachexia. Br. J. Cancer 114, 680–687 (2016).
Zhang, K. L. et al. Integrated neutrophil-to-lymphocyte ratio and handgrip strength better predict survival in patients with cancer cachexia. Nutrition 122, 112399 (2024).
Ruan, G. T. et al. Association of systemic inflammation and overall survival in elderly patients with cancer cachexia – results from a multicenter study. J. Inflamm. Res. 14, 5527–5540 (2021).
Xie, H. et al. Evaluation and validation of neutrophil to albumin ratio as a promising prognostic marker for all-cause mortality in patients with cancer: a multicenter cohort study. Nutrition 121, 112365 (2024).
Xie, H. L. et al. The prognostic value of the combination of body composition and systemic inflammation in patients with cancer cachexia. J. Cachexia Sarcopenia Muscle 14, 879–890 (2023).
Peterson, J. M., Feeback, K. D., Baas, J. H. & Pizza, F. X. Tumor necrosis factor-alpha promotes the accumulation of neutrophils and macrophages in skeletal muscle. J. Appl Physiol. 101, 1394–1399 (2006).
Petruzzelli, M. et al. Early Neutrophilia marked by aerobic glycolysis sustains host metabolism and delays cancer cachexia. Cancers. 14, 963 (2022).
Hayashi, Y. et al. IL36G-producing neutrophil-like monocytes promote cachexia in cancer. Nat. Commun. 15, 7662 (2024).
Wang, D. et al. LCN2 secreted by tissue-infiltrating neutrophils induces the ferroptosis and wasting of adipose and muscle tissues in lung cancer cachexia. J. Hematol. Oncol. 16, 30 (2023).
Narsale, A. et al. Cancer-driven changes link T-cell frequency to muscle strength in people with cancer: a pilot study. J. Cachexia Sarcopenia Muscle 10, 827–843 (2019).
Ju, J. E. et al. Potential role of immunological factors in early diagnosis of cancer cachexia in C26 tumor-bearing mice. Appl Biol. Chem. 62, 3 (2019).
Collinson-Pautz, M. R. et al. Constitutively active MyD88/CD40 costimulation enhances expansion and efficacy of chimeric antigen receptor T cells targeting hematological malignancies. Leukemia 33, 2195–2207 (2019).
Wang, Z., Zhao, C., Moya, R. & Davies, J. D. A novel role for CD4+ T cells in the control of cachexia. J. Immunol. 181, 4676–4684 (2008).
Anoveros-Barrera, A. et al. Immunohistochemical phenotyping of T cells, granulocytes, and phagocytes in the muscle of cancer patients: association with radiologically defined muscle mass and gene expression. Skelet. Muscle 9, 24 (2019).
Michaelis, K. A. et al. The TLR7/8 agonist R848 remodels tumor and host responses to promote survival in pancreatic cancer. Nat. Commun. 10, 4682 (2019).
Baazim, H. et al. CD8(+) T cells induce cachexia during chronic viral infection. Nat. Immunol. 20, 701–710 (2019).
Macciò, A. & Madeddu, C. Blocking inflammation to improve immunotherapy of advanced cancer. Immunology 159, 357–364 (2020).
Gonda, K. et al. Multiple immunological mechanisms of cancer cachexia in patients with solid tumors. J. Clin. Oncol. 34, 667–667 (2016).
Shibata, M. et al. Abstract 1285: Production of interleukin-17 is increased in patients with gastrointestinal cancer and correlates with immune suppression involving MDSC, nutritional impairment, and poor prognosis. Cancer Res. 75, 1285–1285 (2015).
Yang, J. et al. Abstract 4695: dual targeting of MEK and PI3K pathways can act via tumor-intrinsic mechanisms to overcome resistance and tumor-extrinsic mechanisms to modulate immunity and limit cancer cachexia. Cancer Res. 75, 4695–4695 (2015).
Cuenca, A. G. et al. Novel role for tumor-induced expansion of myeloid-derived cells in cancer cachexia. J. Immunol. 192, 6111–6119 (2014).
Winfield, R. D. et al. Myeloid-derived suppressor cells in cancer cachexia syndrome: a new explanation for an old problem. JPEN J. Parenter. Enter. Nutr. 32, 651–655 (2008).
Ghonim, M. A. et al. Targeting PARP-1 with metronomic therapy modulates MDSC suppressive function and enhances anti-PD-1 immunotherapy in colon cancer. J. Immunother. Cancer. 9, e001643 (2021).
Dzierlega, K. et al. Activin A-expressing polymorphonuclear myeloid-derived suppressor cells infiltrate skeletal and cardiac muscle and promote cancer cachexia. J. Immunol. 211, 497–507 (2023).
Deyhle, M. R. et al. Depleting Ly6G positive myeloid cells reduces pancreatic cancer-induced skeletal muscle atrophy. Cells 11, 1893 (2022).
VanderVeen, B. N. et al. The complex heterogeneity of immune cell signatures across wasting tissues with C26 and 5-fluorouracil-induced cachexia. Am. J. Physiol. Cell Physiol. 326, C606–c621 (2024).
Nissinen, T. A. et al. Treating cachexia using soluble ACVR2B improves survival, alters mTOR localization, and attenuates liver and spleen responses. J. Cachexia Sarcopenia Muscle 9, 514–529 (2018).
Lima, J. et al. Tumor-derived transforming growth factor-β signaling contributes to fibrosis in patients with cancer cachexia. J. Cachexia Sarcopenia Muscle 10, 1045–1059 (2019).
Zhao, Y. et al. circNOX4 activates an inflammatory fibroblast niche to promote tumor growth and metastasis in NSCLC via FAP/IL-6 axis. Mol. Cancer 23, 47 (2024).
Zeng, W. et al. CCL18 signaling from tumor-associated macrophages activates fibroblasts to adopt a chemoresistance-inducing phenotype. Oncogene 42, 224–237 (2023).
Bruzzese, F. et al. Local and systemic protumorigenic effects of cancer-associated fibroblast-derived GDF15. Cancer Res. 74, 3408–3417 (2014).
Rettig, W. J. et al. Cell-surface glycoproteins of human sarcomas: differential expression in normal and malignant tissues and cultured cells. Proc. Natl. Acad. Sci. USA 85, 3110–3114 (1988).
Feig, C. et al. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc. Natl. Acad. Sci. USA 110, 20212–20217 (2013).
Yang, X. et al. FAP promotes immunosuppression by cancer-associated fibroblasts in the tumor microenvironment via STAT3-CCL2 signaling. Cancer Res. 76, 4124–4135 (2016).
Zhao, L. et al. Antitumor efficacy and potential mechanism of FAP-targeted radioligand therapy combined with immune checkpoint blockade. Signal Transduct. Target Ther. 9, 142 (2024).
Tran, E. et al. Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia. J. Exp. Med. 210, 1125–1135 (2013).
Roberts, E. W. et al. Depletion of stromal cells expressing fibroblast activation protein-α from skeletal muscle and bone marrow results in cachexia and anemia. J. Exp. Med. 210, 1137–1151 (2013).
Maishi, N. & Hida, K. Tumor endothelial cells accelerate tumor metastasis. Cancer Sci. 108, 1921–1926 (2017).
Inda, A. M. et al. Evaluation of angiogenesis with the expression of VEGF and CD34 in human non-small cell lung cancer. J. Exp. Clin. Cancer Res. 26, 375–378 (2007).
Tichet, M. et al. Tumor-derived SPARC drives vascular permeability and extravasation through endothelial VCAM1 signaling to promote metastasis. Nat. Commun. 6, 6993 (2015).
Husain, A., Hu, N., Sadow, P. M. & Nucera, C. Expression of angiogenic switch, cachexia and inflammation factors at the crossroad in undifferentiated thyroid carcinoma with BRAF(V600E). Cancer Lett. 380, 577–585 (2016).
Hsu, B. G. et al. Association of endothelial dysfunction and peripheral arterial disease with sarcopenia in chronic kidney disease. J. Cachexia Sarcopenia Muscle 15, 1199–1208 (2024).
Kim, Y.-M. et al. Skeletal muscle endothelial dysfunction through the activin A-PGC1α axis drives progression of cancer cachexia. Nat. Cancer 6, 1835–1845 (2025).
Yang, S. et al. Functional effects of muscle PGC-1alpha in aged animals. Skelet. Muscle 10, 14 (2020).
Banks, W. A. Anorectic effects of circulating cytokines: role of the vascular blood‒brain barrier. Nutrition 17, 434–437 (2001).
Sun, M. et al. Endothelial peroxynitrite causes disturbance of neuronal oscillations by targeting caspase-1 in the arcuate nucleus. Redox Biol. 47, 102147 (2021).
Ling, T., Liu, J., Dong, L. & Liu, J. The roles of P-selectin in cancer cachexia. Med. Oncol. 40, 338 (2023).
Taylor, J. et al. Endothelial Notch1 signaling in white adipose tissue promotes cancer cachexia. Nat. Cancer 4, 1544–1560 (2023).
Klose, R. et al. Targeting VEGF-A in myeloid cells enhances natural killer cell responses to chemotherapy and ameliorates cachexia. Nat. Commun. 7, 12528 (2016).
Widner, D. B. et al. Activated mast cells in skeletal muscle can be a potential mediator for cancer-associated cachexia. J. Cachexia Sarcopenia Muscle 12, 1079–1097 (2021).
Cho, D. S. et al. Single-cell deconstruction of post-sepsis skeletal muscle and adipose tissue microenvironments. J. Cachexia Sarcopenia Muscle 11, 1351–1363 (2020).
Morvan, M. G. & Lanier, L. L. NK cells and cancer: you can teach innate cells new tricks. Nat. Rev. Cancer 16, 7–19 (2016).
Baazim, H., Antonio-Herrera, L. & Bergthaler, A. The interplay of immunology and cachexia in infection and cancer. Nat. Rev. Immunol. 22, 309–321 (2022).
Yeh, S. S. & Schuster, M. W. Geriatric cachexia: the role of cytokines. Am. J. Clin. Nutr. 70, 183–197 (1999).
Scarlett, J. M. et al. Regulation of central melanocortin signaling by interleukin-1 beta. Endocrinology 148, 4217–4225 (2007).
Marks, D. L. et al. Differential role of melanocortin receptor subtypes in cachexia. Endocrinology 144, 1513–1523 (2003).
Whitaker, K. W. & Reyes, T. M. Central blockade of melanocortin receptors attenuates the metabolic and locomotor responses to peripheral interleukin-1beta administration. Neuropharmacology 54, 509–520 (2008).
Ericsson, A., Kovács, K. J. & Sawchenko, P. E. A functional anatomical analysis of central pathways subserving the effects of interleukin-1 on stress-related neuroendocrine neurons. J. Neurosci. 14, 897–913 (1994).
Braun, T. P. et al. Central nervous system inflammation induces muscle atrophy via activation of the hypothalamic‒pituitary‒adrenal axis. J. Exp. Med. 208, 2449–2463 (2011).
Krelin, Y. et al. Interleukin-1beta-driven inflammation promotes the development and invasiveness of chemical carcinogen-induced tumors. Cancer Res. 67, 1062–1071 (2007).
Grossberg, A. J. et al. Arcuate nucleus proopiomelanocortin neurons mediate the acute anorectic actions of leukemia inhibitory factor via gp130. Endocrinology 151, 606–616 (2010).
Hirano, T. et al. Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature 324, 73–76 (1986).
Kopf, M. et al. Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature 368, 339–342 (1994).
Soler, M. F. et al. New perspectives in cancer immunotherapy: targeting IL-6 cytokine family. J. Immunother. Cancer 11, e007530 (2023).
Hunter, C. A. & Jones, S. A. IL-6 as a keystone cytokine in health and disease. Nat. Immunol. 16, 448–457 (2015).
Wolf, J., Rose-John, S. & Garbers, C. Interleukin-6 and its receptors: a highly regulated and dynamic system. Cytokine 70, 11–20 (2014).
Bonetto, A. et al. JAK/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia. Am. J. Physiol. Endocrinol. Metab. 303, E410–E421 (2012).
Zimmers, T. A., Fishel, M. L. & Bonetto, A. STAT3 in the systemic inflammation of cancer cachexia. Semin. Cell Dev. Biol. 54, 28–41 (2016).
Tsujinaka, T. et al. Interleukin 6 receptor antibody inhibits muscle atrophy and modulates proteolytic systems in interleukin 6 transgenic mice. J. Clin. Investig. 97, 244–249 (1996).
White, J. P. et al. Muscle mTORC1 suppression by IL-6 during cancer cachexia: a role for AMPK. Am. J. Physiol. Endocrinol. Metab. 304, E1042–E1052 (2013).
Magnuson, B., Ekim, B. & Fingar, D. C. Regulation and function of ribosomal protein S6 kinase (S6K) within mTOR signaling networks. Biochem. J. 441, 1–21 (2012).
Mishra, D. et al. Parabrachial interleukin-6 reduces body weight and food intake and increases thermogenesis to regulate energy metabolism. Cell Rep. 26, 3011–3026.e3015 (2019).
Sun, Q. et al. Area postrema neurons mediate interleukin-6 function in cancer cachexia. Nat. Commun. 15, 4682 (2024).
Heredia, J. E. et al. Type 2 innate signals stimulate fibro/adipogenic progenitors to facilitate muscle regeneration. Cell 153, 376–388 (2013).
Meng, J. et al. Accelerated regeneration of the skeletal muscle in RNF13-knockout mice is mediated by macrophage-secreted IL-4/IL-6. Protein Cell 5, 235–247 (2014).
Lu, S. W. et al. IL-20 antagonist suppresses PD-L1 expression and prolongs survival in pancreatic cancer models. Nat. Commun. 11, 4611 (2020).
Beutler, B. et al. Purification of cachectin, a lipoprotein lipase-suppressing hormone secreted by endotoxin-induced RAW 264.7 cells. J. Exp. Med. 161, 984–995 (1985).
Yang, X. et al. Relative contribution of adipose triglyceride lipase and hormone-sensitive lipase to tumor necrosis factor-α (TNF-α)-induced lipolysis in adipocytes. J. Biol. Chem. 286, 40477–40485 (2011).
Li, Y. P. & Reid, M. B. NF-kappaB mediates the protein loss induced by TNF-alpha in differentiated skeletal muscle myotubes. Am. J. Physiol. Regul. Integr. Comp. Physiol. 279, R1165–R1170 (2000).
Yoshida, T. et al. Molecular mechanisms and signaling pathways of angiotensin II-induced muscle wasting: potential therapeutic targets for cardiac cachexia. Int. J. Biochem. Cell Biol. 45, 2322–2332 (2013).
Wang, D. T. et al. Resveratrol prevents TNF-α-induced muscle atrophy via regulation of Akt/mTOR/FoxO1 signaling in C2C12 myotubes. Int. Immunopharmacol. 19, 206–213 (2014).
Patel, H. J. & Patel, B. M. TNF-α and cancer cachexia: molecular insights and clinical implications. Life Sci. 170, 56–63 (2017).
Chen, J. L. et al. Specific targeting of TGF-β family ligands demonstrates distinct roles in the regulation of muscle mass in health and disease. Proc. Natl. Acad. Sci. USA 114, E5266–e5275 (2017).
Walton, K. L., Johnson, K. E. & Harrison, C. A. Targeting TGF-β mediated SMAD signaling for the prevention of fibrosis. Front. Pharmacol. 8, 461 (2017).
Massagué, J. TGFβ signaling in context. Nat. Rev. Mol. Cell Biol. 13, 616–630 (2012).
Lee, S. J. et al. Functional redundancy of type I and type II receptors in the regulation of skeletal muscle growth by myostatin and activin A. Proc. Natl. Acad. Sci. USA 117, 30907–30917 (2020).
Sartori, R., Romanello, V. & Sandri, M. Mechanisms of muscle atrophy and hypertrophy: implications in health and disease. Nat. Commun. 12, 330 (2021).
Domaniku, A., Bilgic, S. N. & Kir, S. Muscle wasting: emerging pathways and potential drug targets. Trends Pharmacol. Sci. 44, 705–718 (2023).
Domaniku-Waraich, A. et al. Oncostatin M signaling drives cancer-associated skeletal muscle wasting. Cell Rep. Med. 5, 101498 (2024).
Bilgic, S. N. et al. EDA2R-NIK signaling promotes muscle atrophy linked to cancer cachexia. Nature 617, 827–834 (2023).
Miki, Y. et al. Oncostatin M induces C2C12 myotube atrophy by modulating muscle differentiation and degradation. Biochem. Biophys. Res. Commun. 516, 951–956 (2019).
Viswanadhapalli, S. et al. Targeting LIF/LIFR signaling in cancer. Genes Dis. 9, 973–980 (2022).
Li, X. & Sun, K. Regulation of lipolysis in adipose tissue and clinical significance. Adv. Exp. Med. Biol. 1090, 199–210 (2018).
Basu, D. & Goldberg, I. J. Regulation of lipoprotein lipase-mediated lipolysis of triglycerides. Curr. Opin. Lipidol. 31, 154–160 (2020).
Arora, G. K. et al. Cachexia-associated adipose loss induced by tumor-secreted leukemia inhibitory factor is counterbalanced by decreased leptin. JCI Insight 3, e121221 (2018).
Terawaki, K. et al. New cancer cachexia rat model generated by implantation of a peritoneal dissemination-derived human stomach cancer cell line. Am. J. Physiol. Endocrinol. Metab. 306, E373–E387 (2014).
Sarraf, P. et al. Multiple cytokines and acute inflammation raise mouse leptin levels: potential role in inflammatory anorexia. J. Exp. Med. 185, 171–175 (1997).
Seto, D. N., Kandarian, S. C. & Jackman, R. W. A key role for leukemia inhibitory factor in C26 cancer cachexia. J. Biol. Chem. 290, 19976–19986 (2015).
Wischhusen, J., Melero, I. & Fridman, W. H. Growth/Differentiation Factor-15 (GDF-15): from biomarker to novel targetable immune checkpoint. Front. Immunol. 11, 951 (2020).
Rochette, L. et al. GDF15 and cardiac cells: current concepts and new insights. Int. J. Mol. Sci. 22, 8889 (2021).
Johnen, H. et al. Tumor-induced anorexia and weight loss are mediated by the TGF-β superfamily cytokine MIC-1. Nat. Med. 13, 1333–1340 (2007).
Cimino, I. et al. Activation of the hypothalamic‒pituitary‒adrenal axis by exogenous and endogenous GDF15. Proc. Natl. Acad. Sci. USA 118, e2106868118 (2021).
Garfield, B. E. et al. Growth/differentiation factor 15 causes TGFβ-activated kinase 1-dependent muscle atrophy in pulmonary arterial hypertension. Thorax 74, 164–176 (2019).
Lerner, L. et al. MAP3K11/GDF15 axis is a critical driver of cancer cachexia. J. Cachexia Sarcopenia Muscle 7, 467–482 (2016).
Elattar, S., Dimri, M. & Satyanarayana, A. The tumor secretory factor ZAG promotes white adipose tissue browning and energy wasting. FASEB J. 32, 4727–4743 (2018).
Westhrin, M. et al. Growth differentiation factor 15 (GDF15) promotes osteoclast differentiation and inhibits osteoblast differentiation and high serum GDF15 levels are associated with multiple myeloma bone disease. Hematologica 100, e511–e514 (2015).
Hao, J. et al. IFN-γ induces lipogenesis in mouse mesangial cells via the JAK2/STAT1 pathway. Am. J. Physiol. Cell Physiol. 304, C760–C767 (2013).
Sun, W. Y. et al. Lipocalin-2 derived from adipose tissue mediates aldosterone-induced renal injury. JCI Insight. 3, e120196 (2018).
Glaviano, A. et al. PI3K/AKT/mTOR signal transduction pathway and targeted therapies in cancer. Mol. Cancer 22, 138 (2023).
Tsigos, C. & Chrousos, G. P. Hypothalamic‒pituitary‒adrenal axis, neuroendocrine factors and stress. J. Psychosom. Res. 53, 865–871 (2002).
Gioldasi, S. et al. Metabolic Association between Leptin and the Corticotropin Releasing Hormone. Endocr. Metab. Immune Disord. Drug Targets 19, 458–466 (2019).
Menconi, M. et al. Role of glucocorticoids in the molecular regulation of muscle wasting. Crit. Care Med. 35, S602–S608 (2007).
Chrousos, G. P. The hypothalamic‒pituitary‒adrenal axis and immune-mediated inflammation. N. Engl. J. Med. 332, 1351–1362 (1995).
Tsigos, C. et al. Dose effects of recombinant human interleukin-6 on pituitary hormone secretion and energy expenditure. Neuroendocrinology 66, 54–62 (1997).
Gupta, R. et al. Multifaceted role of NF-κB in hepatocellular carcinoma therapy: Molecular landscape, therapeutic compounds and nanomaterial approaches. Environ. Res. 228, 115767 (2023).
Shi, P., Xu, J. & Cui, H. The recent research progress of NF-κB signaling on the proliferation, migration, invasion, immune escape and drug resistance of glioblastoma. Int. J. Mol. Sci. 24, (2023).
Miao, C. et al. Pyrrolidine Dithiocarbamate (PDTC) attenuates cancer cachexia by affecting muscle atrophy and fat lipolysis. Front. Pharmacol. 8, 915 (2017).
Paul, P. K. et al. Targeted ablation of TRAF6 inhibits skeletal muscle wasting in mice. J. Cell Biol. 191, 1395–1411 (2010).
Langen, R. C. et al. NF-κB activation is required for the transition of pulmonary inflammation to muscle atrophy. Am. J. Respir. Cell Mol. Biol. 47, 288–297 (2012).
Guttridge, D. C. et al. NF-kappaB-induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia. Science 289, 2363–2366 (2000).
Li, W. et al. Interleukin-1 stimulates catabolism in C2C12 myotubes. Am. J. Physiol. Cell Physiol. 297, C706–C714 (2009).
Hanna, R. A. et al. Microtubule-associated protein 1 light chain 3 (LC3) interacts with Bnip3 protein to selectively remove endoplasmic reticulum and mitochondria via autophagy. J. Biol. Chem. 287, 19094–19104 (2012).
Philips, R. L. et al. The JAK-STAT pathway at 30: Much learned, much more to do. Cell 185, 3857–3876 (2022).
O’Shea, J. J., Holland, S. M. & Staudt, L. M. JAKs and STATs in immunity, immunodeficiency, and cancer. N. Engl. J. Med. 368, 161–170 (2013).
Samra, S., Bergerson, J. R. E., Freeman, A. F. & Turvey, S. E. JAK-STAT signaling pathway, immunodeficiency, inflammation, immune dysregulation, and inborn errors of immunity. J. Allergy Clin. Immunol. 155, 357–367 (2025).
Zhang, L. et al. Stat3 activation links a C/EBPδ to myostatin pathway to stimulate loss of muscle mass. Cell Metab. 18, 368–379 (2013).
Silva, K. A. et al. Inhibition of Stat3 activation suppresses caspase-3 and the ubiquitin‒proteasome system, leading to preservation of muscle mass in cancer cachexia. J. Biol. Chem. 290, 11177–11187 (2015).
Fujita, J. et al. Anti-interleukin-6 receptor antibody prevents muscle atrophy in colon-26 adenocarcinoma-bearing mice with modulation of lysosomal and ATP-ubiquitin-dependent proteolytic pathways. Int. J. Cancer 68, 637–643 (1996).
Hashimoto, S. et al. Exercise-induced vitamin D receptor and androgen receptor mediate inhibition of IL-6 and STAT3 in muscle. Biochem. Biophys. Rep. 37, 101621 (2024).
Testa, M. T. J. et al. Resistance training attenuates activation of STAT3 and muscle atrophy in tumor-bearing mice. Front. Oncol. 12, 880787 (2022).
Oh, H. M. et al. STAT3 protein interacts with Class O Forkhead transcription factors in the cytoplasm and regulates nuclear/cytoplasmic localization of FoxO1 and FoxO3a proteins in CD4(+) T cells. J. Biol. Chem. 287, 30436–30443 (2012).
Yoon, S. et al. NF-κB and STAT3 cooperatively induce IL6 in starved cancer cells. Oncogene 31, 3467–3481 (2012).
Gandhi, A. Y. et al. Cytokine-mediated STAT3 transcription supports ATGL/CGI-58-dependent adipocyte lipolysis in cancer cachexia. Front. Oncol. 12, 841758 (2022).
Abdullahi, A. et al. Browning of white adipose tissue after a burn injury promotes hepatic steatosis and dysfunction. Cell Death Dis. 10, 870 (2019).
Anderson, L. J. et al. Whole-body and adipose tissue metabolic phenotype in cancer patients. J. Cachexia Sarcopenia Muscle 13, 1124–1133 (2022).
Lee, J. H. & Jun, H. S. Role of myokines in regulating skeletal muscle mass and function. Front. Physiol. 10, 42 (2019).
Burks, T. N. & Cohn, R. D. Role of TGF-β signaling in inherited and acquired myopathies. Skelet. Muscle 1, 19 (2011).
Amthor, H. & Hoogaars, W. M. Interference with myostatin/ActRIIB signaling as a therapeutic strategy for Duchenne muscular dystrophy. Curr. Gene Ther. 12, 245–259 (2012).
El Shafey, N. et al. Inhibition of the myostatin/Smad signaling pathway by short decorin-derived peptides. Exp. Cell Res. 341, 187–195 (2016).
Schiaffino, S. et al. Mechanisms regulating skeletal muscle growth and atrophy. FEBS J. 280, 4294–4314 (2013).
Costelli, P. et al. Muscle myostatin signaling is enhanced in experimental cancer cachexia. Eur. J. Clin. Investig. 38, 531–538 (2008).
Zhou, X. et al. Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell 142, 531–543 (2010).
Kramer, H. F. & Goodyear, L. J. Exercise, MAPK, and NF-κB signaling in skeletal muscle. J. Appl. Physiol. 103, 388–395 (2007).
Yang, J. et al. ZIP4 promotes muscle wasting and cachexia in mice with orthotopic pancreatic tumors by stimulating RAB27B-Regulated release of extracellular vesicles from cancer cells. Gastroenterology 156, 722–734.e726 (2019).
Chiappalupi, S. et al. Targeting RAGE prevents muscle wasting and prolongs survival in cancer cachexia. J. Cachexia Sarcopenia Muscle 11, 929–946 (2020).
Perdiguero, E. et al. Genetic analysis of p38 MAP kinases in myogenesis: fundamental role of p38alpha in abrogating myoblast proliferation. EMBO J. 26, 1245–1256 (2007).
Yoon, S. L. & Grundmann, O. Relevance of dietary supplement use in gastrointestinal-cancer-associated cachexia. Nutrients. 15, 3391 (2023).
Coniglio, S., Shumskaya, M. & Vassiliou, E. Unsaturated fatty acids and their immunomodulatory properties. Biology. 12, 279 (2023).
Loyala, J. V., Down, B., Wong, E. & Tan, B. Treatment of cachexia in gastric cancer: exploring the use of anti-inflammatory natural products and their derivatives. Nutrients. 16, 1246 (2024).
Mocellin, M. C., Camargo, C. D. Q., Fabre, M. E. D. S. & Trindade, E. B. S. D. M. Fish oil effects on quality of life, body weight and free fat mass change in gastrointestinal cancer patients undergoing chemotherapy: a triple blind, randomized clinical trial. J. Funct. Foods 31, 113–122 (2017).
Jatoi, A. et al. A double-blind, placebo-controlled randomized trial of creatine for the cancer anorexia/weight loss syndrome (N02C4): an Alliance trial. Ann. Oncol. 28, 1957–1963 (2017).
Inui, A. Cancer anorexia-cachexia syndrome: current issues in research and management. CA Cancer J. Clin. 52, 72–91 (2002).
Tchekmedyian, N. S., Tait, N., Moody, M. & Aisner, J. High-dose megestrol acetate. A possible treatment for cachexia. JAMA 257, 1195–1198 (1987).
Kouchaki, B. et al. Randomized double-blind clinical trial of combined treatment with megestrol acetate plus celecoxib versus megestrol acetate alone in cachexia-anorexia syndrome induced by GI cancers. Support. Care Cancer 26, 2479–2489 (2018).
Kerem, M. et al. Adipokines and ghrelin in gastric cancer cachexia. World J. Gastroenterol. 14, 3633–3641 (2008).
Strasser, F. et al. Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomized, placebo-controlled, double-blind, double-crossover study. Br. J. Cancer 98, 300–308 (2008).
Dev, R., Amano, K., Naito, T. & Del Fabbro, E. Anamorelin for the treatment of cancer anorexia-cachexia syndrome. Curr. Oncol. Rep. 26, 762–772 (2024).
Herodes, M. et al. Pilot clinical trial of macimorelin to assess safety and efficacy in patients with cancer cachexia. J. Cachexia Sarcopenia Muscle 14, 835–846 (2023).
Hamauchi, S. et al. A multicenter, open-label, single-arm study of anamorelin (ONO-7643) in advanced gastrointestinal cancer patients with cancer cachexia. Cancer 125, 4294–4302 (2019).
Iwai, N. et al. Predictors of response to anamorelin in gastrointestinal cancer patients with cachexia: a retrospective study. Support. Care Cancer 31, 115 (2023).
Bar-Sela, G., Zalman, D., Semenysty, V. & Ballan, E. The effects of dosage-controlled cannabis capsules on cancer-related cachexia and anorexia syndrome in advanced cancer patients: pilot study. Integr. Cancer Ther. 18, 1534735419881498 (2019).
Sandhya, L. et al. Randomized double-blind placebo-controlled study of olanzapine for chemotherapy-related anorexia in patients with locally advanced or metastatic gastric, hepatopancreaticobiliary, and lung cancer. J. Clin. Oncol. 41, 2617–2627 (2023).
Riechelmann, R. P. et al. Phase II trial of mirtazapine for cancer-related cachexia and anorexia. Am. J. Hosp. Palliat. Care. 27, 106–110 (2010).
Almeida, O. L. S. et al. Mirtazapine versus megestrol in the treatment of anorexia-cachexia syndrome in patients with advanced cancer: a randomized, double-blind, controlled phase II clinical trial. Cancers. 15, 3588 (2023).
Hickish, T. et al. MABp1 as a novel antibody treatment for advanced colorectal cancer: a randomized, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 18, 192–201 (2017).
Wang, R. et al. Curcumin treatment suppresses cachexia-associated adipose wasting in mice by blocking the cAMP/PKA/CREB signaling pathway. Phytomedicine 109, 154563 (2023).
Chaiworramukkul, A., Seetalarom, K., Saichamchan, S. & Prasongsook, N. A double-blind, placebo-controlled randomized phase IIa study: evaluating the effect of curcumin for treatment of cancer anorexia-cachexia syndrome in solid cancer patients. Asian Pac. J. Cancer Prev. 23, 2333–2340 (2022).
Lai, V. et al. Results of a pilot study of the effects of celecoxib on cancer cachexia in patients with cancer of the head, neck, and gastrointestinal tract. Head. Neck 30, 67–74 (2008).
Mantovani, G. et al. Phase II nonrandomized study of the efficacy and safety of COX-2 inhibitor celecoxib on patients with cancer cachexia. J. Mol. Med. 88, 85–92 (2010).
Jatoi, A. et al. A placebo-controlled double blind trial of etanercept for the cancer anorexia/weight loss syndrome: results from N00C1 from the North Central Cancer Treatment Group. Cancer 110, 1396–1403 (2007).
Davis, M. et al. A Phase II dose titration study of thalidomide for cancer-associated anorexia. J. Pain. Symptom Manag. 43, 78–86 (2012).
Yennurajalingam, S. et al. The role of thalidomide and placebo for the treatment of cancer-related anorexia-cachexia symptoms: results of a double-blind placebo-controlled randomized study. J. Palliat. Med. 15, 1059–1064 (2012).
Wen, H. S. et al. Clinical studies on the treatment of cancer cachexia with megestrol acetate plus thalidomide. Chemotherapy 58, 461–467 (2012).
Chasen, M., Hirschman, S. Z. & Bhargava, R. Phase II study of the novel peptide-nucleic acid OHR118 in the management of cancer-related anorexia/cachexia. J. Am. Med. Dir. Assoc. 12, 62–67 (2011).
Hauer, K. et al. Improvement in muscular performance and decrease in tumor necrosis factor level in old age after antioxidant treatment. J. Mol. Med. 81, 118–125 (2003).
Lundholm, K. et al. Insulin treatment in cancer cachexia: effects on survival, metabolism, and physical functioning. Clin. Cancer Res. 13, 2699–2706 (2007).
Hsu, J. Y. et al. Non-homeostatic body weight regulation through a brainstem-restricted receptor for GDF15. Nature 550, 255–259 (2017).
Breen, D. M. et al. GDF-15 neutralization alleviates platinum-based chemotherapy-induced emesis, anorexia, and weight loss in mice and nonhuman primates. Cell Metab. 32, 938–950.e936 (2020).
Lerner, L. et al. Plasma growth differentiation factor 15 is associated with weight loss and mortality in cancer patients. J. Cachexia Sarcopenia Muscle 6, 317–324 (2015).
Crawford, J. et al. A Phase Ib first-in-patient study assessing the safety, tolerability, pharmacokinetics, and pharmacodynamics of ponsegromab in participants with cancer and cachexia. Clin. Cancer Res. 30, 489–497 (2024).
Groarke, J. D. et al. Ponsegromab for the treatment of cancer cachexia. N. Engl. J. Med. 391, 2291–2303 (2024).
Chen, J. L. et al. Elevated expression of activins promotes muscle wasting and cachexia. FASEB J. 28, 1711–1723 (2014).
Christopher, C. N. et al. Exercise and nutrition interventions for prehabilitation in hepato-pancreato-biliary cancers: a narrative review. Nutrients. 15, 5044 (2023).
Gukovsky, I. et al. Inflammation, autophagy, and obesity: common features in the pathogenesis of pancreatitis and pancreatic cancer. Gastroenterology 144, 1199–1209.e1194 (2013).
Gordon, J. N. et al. Thalidomide in the treatment of cancer cachexia: a randomized placebo controlled trial. Gut 54, 540–545 (2005).
Wiedenmann, B. et al. A multicenter, phase II study of infliximab plus gemcitabine in pancreatic cancer cachexia. J. Support. Oncol. 6, 18–25 (2008).
Kraft, M. et al. L-Carnitine-supplementation in advanced pancreatic cancer (CARPAN)–a randomized multicenter trial. Nutr. J. 11, 52 (2012).
Khan, S. A., Thomas, H. C., Davidson, B. R. & Taylor-Robinson, S. D. Cholangiocarcinoma. Lancet 366, 1303–1314 (2005).
Bekaii-Saab, T. et al. Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers. J. Clin. Oncol. 29, 2357–2363 (2011).
Prado, C. M. et al. Skeletal muscle anabolism is a side effect of therapy with the MEK inhibitor: selumetinib in patients with cholangiocarcinoma. Br. J. Cancer 106, 1583–1586 (2012).
Finn, R. S. et al. Phase 1b investigation of the MEK inhibitor binimetinib in patients with advanced or metastatic biliary tract cancer. Investig. N. Drugs 36, 1037–1043 (2018).
Yuan, L. et al. The atypical β-blocker S-oxprenolol reduces cachexia and improves survival in a rat cancer cachexia model. J. Cachexia Sarcopenia Muscle 14, 653–660 (2023).
Stewart et al. Espindolol for the treatment and prevention of cachexia in patients with stage III/IV non-small cell lung cancer or colorectal cancer: a randomized, double-blind, placebo-controlled, international multicenter phase II study (the ACT-ONE trial). J. Cachexia Sarcopenia Muscle 7, 355–365 (2016).
Pötsch, M. S. et al. MT-102 prevents tissue wasting and improves survival in a rat model of severe cancer cachexia. J. Cachexia Sarcopenia Muscle 11, 594–605 (2020).
Sung, H. et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 71, 209–249 (2021).
Op den Kamp, C. M. et al. Pre-cachexia in patients with stages I-III non-small cell lung cancer: systemic inflammation and functional impairment without activation of skeletal muscle ubiquitin proteasome system. Lung Cancer 76, 112–117 (2012).
Cortiula, F. et al. Physical exercise at the crossroad between muscle wasting and the immune system: implications for lung cancer cachexia. J. Cachexia Sarcopenia Muscle 13, 55–67 (2022).
Arrieta, O. et al. Mirtazapine as appetite stimulant in patients with non-small cell lung cancer and anorexia: a randomized clinical trial. JAMA Oncol. 10, 305–314 (2024).
Turcott, J. G. et al. The effect of nabilone on appetite, nutritional status, and quality of life in lung cancer patients: a randomized, double-blind clinical trial. Support. Care Cancer 26, 3029–3038 (2018).
Crawford, J. et al. Study design and rationale for the phase 3 clinical development program of enobosarm, a selective androgen receptor modulator, for the prevention and treatment of muscle wasting in cancer patients (POWER Trials). Curr. Oncol. Rep. 18, 37 (2016).
Bohl, C. E. et al. Structural basis for accommodation of nonsteroidal ligands in the androgen receptor. J. Biol. Chem. 280, 37747–37754 (2005).
Dobs, A. S. et al. Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomized controlled phase 2 trial. Lancet Oncol. 14, 335–345 (2013).
Setiawan, T. et al. Cancer cachexia: molecular mechanisms and treatment strategies. J. Hematol. Oncol. 16, 54 (2023).
Stewart et al. The ACT-ONE trial, a multicenter, randomized, double-blind, placebo-controlled, dose-finding study of the anabolic/catabolic transforming agent, MT-102 in subjects with cachexia related to stage III and IV non-small cell lung cancer and colorectal cancer: study design. J. Cachexia Sarcopenia Muscle 2, 201–207 (2011).
Zhang, H. & Garcia, J. M. Anamorelin hydrochloride for the treatment of cancer-anorexia-cachexia in NSCLC. Expert Opin. Pharmacother. 16, 1245–1253 (2015).
Northrup, R. et al. Effect of ghrelin and anamorelin (ONO-7643), a selective ghrelin receptor agonist, on tumor growth in a lung cancer mouse xenograft model. Support. Care Cancer 21, 2409–2415 (2013).
Temel, J. S. et al. Anamorelin in patients with non-small cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomized, double-blind, phase 3 trials. Lancet Oncol. 17, 519–531 (2016).
Currow, D. et al. ROMANA 3: a phase 3 safety extension study of anamorelin in advanced non-small cell lung cancer (NSCLC) patients with cachexia. Ann. Oncol. 28, 1949–1956 (2017).
Takayama, K. et al. Anamorelin (ONO-7643) in Japanese patients with non-small cell lung cancer and cachexia: results of a randomized phase 2 trial. Support. Care Cancer 24, 3495–3505 (2016).
Katakami, N. et al. Anamorelin (ONO-7643) for the treatment of patients with non-small cell lung cancer and cachexia: Results from a randomized, double-blind, placebo-controlled, multicenter study of Japanese patients (ONO-7643-04). Cancer 124, 606–616 (2018).
Nakanishi, Y., Higuchi, J., Honda, N. & Komura, N. Pharmacological profile and clinical efficacy of anamorelin HCl (ADLUMIZ(®)Tablets), the first orally available drug for cancer cachexia with ghrelin-like action in Japan]. Nihon Yakurigaku Zasshi 156, 370–381 (2021).
Kwon, M. et al. Prevalence and clinical significance of cancer cachexia based on time from treatment in advanced-stage head and neck squamous cell carcinoma. Head. Neck 39, 716–723 (2017).
Muthanandam, S. & Muthu, J. Understanding cachexia in head and neck cancer. Asia Pac. J. Oncol. Nurs. 8, 527–538 (2021).
McQuellon, R. P. et al. Supportive use of megestrol acetate (Megace) with head/neck and lung cancer patients receiving radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 52, 1180–1185 (2002).
Yeh, K. Y. et al. Omega-3 fatty acid-, micronutrient-, and probiotic-enriched nutrition helps body weight stabilization in head and neck cancer cachexia. Oral. Surg. Oral. Med Oral. Pathol. Oral. Radio. 116, 41–48 (2013).
Pottel, L. et al. Echium oil is not protective against weight loss in head and neck cancer patients undergoing curative radio(chemo)therapy: a randomized-controlled trial. BMC Complement. Altern. Med. 14, 382 (2014).
Thambamroong, T. et al. Efficacy of curcumin on treating cancer anorexia-cachexia syndrome in locally or advanced head and neck cancer: a double-blind, placebo-controlled randomized phase IIa Trial (CurChexia). J. Nutr. Metab. 2022, 5425619 (2022).
Rossetti, M. L., Steiner, J. L. & Gordon, B. S. Androgen-mediated regulation of skeletal muscle protein balance. Mol. Cell Endocrinol. 447, 35–44 (2017).
Wright, T. J. et al. A randomized trial of adjunct testosterone for cancer-related muscle loss in men and women. J. Cachexia Sarcopenia Muscle 9, 482–496 (2018).
Goldberg, J. E. & Schwertfeger, K. L. Proinflammatory cytokines in breast cancer: mechanisms of action and potential targets for therapeutics. Curr. Drug Targets 11, 1133–1146 (2010).
Paixão, E. et al. The effects of EPA and DHA enriched fish oil on nutritional and immunological markers of treatment naïve breast cancer patients: a randomized double-blind controlled trial. Nutr. J. 16, 71 (2017).
Khatri, U. et al. Selpercatinib mitigates cancer cachexia independent of anti-tumor activity in the HT1080 tumor model. Cancer Lett. 611, 217444 (2025).
Hsu, J. Y. et al. Erratum: non-homeostatic body weight regulation through a brainstem-restricted receptor for GDF15. Nature 551, 398 (2017).
Mullican, S. E. et al. GFRAL is the receptor for GDF15 and the ligand promotes weight loss in mice and nonhuman primates. Nat. Med. 23, 1150–1157 (2017).
Liu, M., Li, L., Jin, D. & Liu, Y. Nanobody-A versatile tool for cancer diagnosis and therapeutics. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol 13, e1697 (2021).
Huang, Y. et al. GB18-06, a nanobody targeting GDF15, effectively alleviates weight loss and restores physical function in cachexia models. MAbs 16, 2416453 (2024).
Konrad, D. & Wueest, S. The gut-adipose-liver axis in the metabolic syndrome. Physiol. 29, 304–313 (2014).
Matsubara, Y. et al. Organ and brain crosstalk: the liver-brain axis in gastrointestinal, liver, and pancreatic diseases. Neuropharmacology 205, 108915 (2022).
Zaiss, M. M., Jones, R. M., Schett, G. & Pacifici, R. The gut-bone axis: how bacterial metabolites bridge the distance. J. Clin. Investig. 129, 3018–3028 (2019).
Gómez-Ambrosi, J., Rodríguez, A., Catalán, V. & Frühbeck, G. The bone-adipose axis in obesity and weight loss. Obes. Surg. 18, 1134–1143 (2008).
Gray, J. S., Wani, S. A. & Campbell, M. J. Epigenomic alterations in cancer: mechanisms and therapeutic potential. Clin. Sci. 136, 473–492 (2022).
Tseng, Y. C. et al. Preclinical investigation of the novel histone deacetylase inhibitor AR-42 in the treatment of cancer-induced cachexia. J. Natl Cancer Inst. 107, djv274 (2015).
Kottorou, A., Dimitrakopoulos, F. I. & Tsezou, A. Non-coding RNAs in cancer-associated cachexia: clinical implications and future perspectives. Transl. Oncol. 14, 101101 (2021).
Shi, X. et al. Circular RNA ANAPC7 inhibits tumor growth and muscle wasting via PHLPP2-AKT-TGF-β signaling axis in pancreatic cancer. Gastroenterology 162, 2004–2017.e2002 (2022).
Han, J., Meng, Q., Shen, L. & Wu, G. Interleukin-6 induces fat loss in cancer cachexia by promoting white adipose tissue lipolysis and browning. Lipids Health Dis. 17, 14 (2018).
Bodine, S. C. et al. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 294, 1704–1708 (2001).
Aiello, D., Patel, K. & Lasagna, E. The myostatin gene: an overview of mechanisms of action and its relevance to livestock animals. Anim. Genet. 49, 505–519 (2018).
Shintaku, J. et al. MyoD regulates skeletal muscle oxidative metabolism cooperatively with alternative NF-κB. Cell Rep. 17, 514–526 (2016).
Bailey, J. L., Hang, H., Boudreau, A. & Elks, C. M. Oncostatin M Induces lipolysis and suppresses insulin response in 3T3-L1 Adipocytes. Int. J. Mol. Sci. 23, 4689 (2022).
Johnen, H. et al. Tumor-induced anorexia and weight loss are mediated by the TGF-beta superfamily cytokine MIC-1. Nat. Med. 13, 1333–1340 (2007).
Fouladiun, M. et al. Body composition and time course changes in regional distribution of fat and lean tissue in unselected cancer patients on palliative care–correlations with food intake, metabolism, exercise capacity, and hormones. Cancer 103, 2189–2198 (2005).
Iguchi, H. et al. Involvement of parathyroid hormone-related protein in experimental cachexia induced by a human lung cancer-derived cell line established from a bone metastasis specimen. Int. J. Cancer 94, 24–27 (2001).
Cabedo Martinez, A. I. et al. Biochemical and structural characterization of the interaction between the siderocalin NGAL/LCN2 (Neutrophil Gelatinase-associated Lipocalin/Lipocalin 2) and the N-terminal domain of its endocytic receptor SLC22A17. J. Biol. Chem. 291, 2917–2930 (2016).
Garcia, J. M. et al. Anamorelin for patients with cancer cachexia: an integrated analysis of two phase 2, randomized, placebo-controlled, double-blind trials. Lancet Oncol. 16, 108–116 (2015).
Garcia, J. M., Friend, J. & Allen, S. Therapeutic potential of anamorelin, a novel, oral ghrelin mimetic, in patients with cancer-related cachexia: a multicenter, randomized, double-blind, crossover, pilot study. Support. Care Cancer 21, 129–137 (2013).
Golan, T. et al. LY2495655, an antimyostatin antibody, in pancreatic cancer: a randomized, phase 2 trial. J. Cachexia Sarcopenia Muscle 9, 871–879 (2018).
Jatoi, A. et al. A placebo-controlled, double-blind trial of infliximab for cancer-associated weight loss in elderly and/or poor performance non-small cell lung cancer patients (N01C9). Lung Cancer 68, 234–239 (2010).
Del Fabbro, E. et al. Effects of melatonin on appetite and other symptoms in patients with advanced cancer and cachexia: a double-blind placebo-controlled trial. J. Clin. Oncol. 31, 1271–1276 (2013).
Beijer, S. et al. Effect of adenosine 5’-triphosphate infusions on the nutritional status and survival of preterminal cancer patients. Anticancer Drugs 20, 625–633 (2009).
Cuvelier, G. D. et al. A randomized, double-blind, placebo-controlled clinical trial of megestrol acetate as an appetite stimulant in children with weight loss due to cancer and/or cancer therapy. Pediatr. Blood Cancer 61, 672–679 (2014).
Couluris, M. et al. The effect of cyproheptadine hydrochloride (periactin) and megestrol acetate (megace) on weight in children with cancer/treatment-related cachexia. J. Pediatr. Hematol. Oncol. 30, 791–797 (2008).
Laviano, A., Muscaritoli, M. & Rossi-Fanelli, F. Phase II study of high-dose fish oil capsules for patients with cancer-related cachexia: a Cancer and Leukemia Group B study. Cancer 103, 651–652 (2005).
Abe, K. et al. Effects of ω-3 fatty acid supplementation in patients with bile duct or pancreatic cancer undergoing chemotherapy. Anticancer Res. 38, 2369–2375 (2018).
Cheon, C. et al. Efficacy and safety of Sipjeondaebo-Tang for Anorexia in Patients with cancer: a pilot, randomized, double-blind, placebo-controlled trial. Evid. Based Complement. Altern. Med. 2017, 8780325 (2017).
de Clercq, N. C. et al. Fecal microbiota transplantation from overweight or obese donors in cachectic patients with advanced gastroesophageal cancer: a randomized, double-blind, placebo-controlled, phase II study. Clin. Cancer Res. 27, 3784–3792 (2021).